Female directors are quicker to recall dangerous medical products, study shows

March 30, 2020

Medical product recalls number in the thousands each year. In the first quarter of 2018, for example, 84 pharmaceutical companies in the U.S. reported at least one recall. Some 4,500 Food and Drug Administration-approved drugs and devices are pulled from shelves annually -- decisions greatly influenced by the presence of women on a firm's board, according to new research from the University of Notre Dame.

Severe product problems that injure or kill consumers are recalled much faster when there are women on the board, and lower-severity product defects that can be hidden from regulators and not recalled are less often hidden when there are female directors, according to "The Influence of Female Directors on Product Recall Decisions," forthcoming at Manufacturing & Service Operations Management from lead author Kaitlin Wowak, assistant professor of information technology, analytics and operations in Notre Dame's Mendoza College of Business.

Wowak, along with co-authors George Ball at Indiana University, Corinne Post at Lehigh University and David Ketchen at Auburn University, found that compared to boards composed of all male directors, those with female members announce high-severity recalls 28 days faster, a 35 percent reduction in recall timing -- truly a matter of life or death, according to Wowak.

The researchers analyzed 4,271 medical product recalls from 2002 to 2013 across 92 publicly traded firms regulated by the FDA.

Additionally, they found the more women on the board, the more efficient recalls become. While consumers have the most to gain from faster recalls of defective products, Wowak notes, firms have the most to lose since recalls expose them to the most public, regulatory and stock market penalties. As such, the study shows high-risk decisions require more female input to push firms to act faster.

"Just one female director is insufficient to push firms to recall these serious problems more quickly," Wowak explains. "It takes at least two female directors to influence the timeliness of severe product recalls, and three moves things along even faster."

However, in instances involving low-severity recalls that could be hidden from regulators, even having one women at the boardroom table makes a difference. Firms with female directors announce 120 percent more low-severity, high-discretion recalls than firms with all-male boards.

"In this case, just one female director can influence how these decisions are made," Wowak says, "and the number of low-severity recalls announced continues to increase as firms add each additional female director."

"We believe our study shows that there is a difference in very real and important outcomes between firms who add women to their boards and those who don't," she says. "More broadly, we align with recent calls for all directors on boards to look beyond the bottom line and be more responsive to all stakeholders, especially when products may harm or kill their customers or other stakeholders."

University of Notre Dame

Related Decisions Articles from Brightsurf:

Consumers value difficult decisions over easy choices
In a paper co-authored by Gaurav Jain, an assistant professor of marketing in the Lally School of Management at Rensselaer, researchers found that disfluency, or the difficulty for an individual to process a message, increases people's attitudes toward that message after a time delay.

Evolutionary theory of economic decisions
When survival over generations is the end game, researchers say it makes sense to undervalue long shots that could be profitable and overestimate the likelihood of rare bad outcomes.

Decisions made for incapacitated patients often not what families want
Researchers from Regenstrief Institute and Indiana University report in a study published in JAMA Network Open that nearly half of the time medical treatments and orders received for incapacitated patients were not compatible with goals of care requested by their surrogate decision makers.

Which COVID-19 models should we use to make policy decisions?
A new process to harness multiple disease models for outbreak management has been developed by an international team of researchers.

For complex decisions, narrow them down to two
When choosing between multiple alternatives, people usually focus their attention on the two most promising options.

Fungal decisions can affect climate
Research shows fungi may slow climate change by storing more carbon.

How decisions unfold in a zebrafish brain
Researchers were able to track the activity of each neuron in the entire brain of zebrafish larvae and reconstruct the unfolding of neuronal events as the animals repeatedly made 'left or right' choices in a behavioral experiment.

Best of the best: Who makes the most accurate decisions in expert groups?
New method predicts accuracy on the basis of similarity.

How do brains remember decisions?
Mammal brains -- including those of humans -- store and recall impressive amounts of information based on our good and bad decisions and interactions in an ever-changing world.

How we make complex decisions
MIT neuroscientists have identified a brain circuit that helps break complex decisions down into smaller pieces.

Read More: Decisions News and Decisions Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.